Added to YB: 2025-10-02
Pitch date: 2025-09-30
SIGHT.PA [neutral]
GenSight Biologics S.A.
-47.13%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system.
Market Cap
EUR 26.2M
Pitch Price
EUR 0.17
Price Target
N/A
Dividend
N/A
EV/EBITDA
-3.09
P/E
-1.41
EV/Sales
47.58
Sector
Biotechnology
Category
special_situation
Gensight Biologics (SIGHT France): Focus narrows to LUMEVOQ as financing and timelines dominate the agenda
SIGHT.PA (quick overview): Gene therapy LUMEVOQ for inherited retinal diseases awaits French compassionate access launch (coming months) as key catalyst. Cost-cutting extends cash runway to next milestone. Regulatory hurdles include dose-ranging data requests. Phase 3 RECOVER trial 2026, needs partnerships/funding.
Read full article (2 min)